With more than 1,300 people dedicated to oncology, our people and culture are an integral part of our long-term success.
We combine rigorous science, innovative commercial operations and the aspiration of transforming cancer from a serious disease to a treatable illness in our efforts to develop novel medicines — all while working with people brimming with passion and intellect. This is fundamental to our culture and something that is carefully protected and enriched by our leadership.
Starting with our senior leadership, our unique, vibrant and enterprising culture flows through our organization with great vigor and resiliency. Individually and collectively, our senior leaders embody our genuine commitment to patients and our corporate philosophy and personality — how we act and interact, what we are committed to and how we conduct our business.
Throughout our organization, we believe that our work is more than just a job, because we focus on what's important first: the people who rely on our novel medicines. The rest builds upon itself through our integrity, perseverance and aspiration.
Comprised of Takeda's global oncology commercial operations, Takeda Oncology operates in close alignment with Takeda's dedicated global oncology R&D function, the Oncology Therapeutic Area Unit (OTAU), to drive forward the company's products while maintaining a focus on expanding our oncology pipeline.
The organizational structure and governance model for Takeda Oncology is designed to drive customer proximity, nimbleness, agility and accountability. Consistent with these principles, Takeda Oncology operates with a relatively flat organization that allows close proximity to patients and customers, so that we can deeply understand and address their unique and changing needs.
Takeda Oncology is comprised of the following functions and led by the following individuals:
TERESA BITETTI
President, Global Oncology Business Unit
CHRIS ARENDT
Head, Oncology Therapeutic Area Unit
ANA CARDOSA
Head, Human Resources, Global Oncology Business Unit
FRANCESCO DI MARCO
Head, Europe and Canada Oncology
FABIEN DUBOIS
Head, Finance, Global Oncology Business Unit
TAKA HORII
Head, Japan Oncology Business Unit
LIZ LEWIS
Chief Counsel, Specialty BUs & R&D (US) and Head, Patient Advocacy, Global Oncology Business Unit
CRISTIN MCARDLE
Head Counsel, Global Oncology Business Unit
ROSA NOTAROBERTO
Head, Business Operations, Global Oncology Business Unit
MAURICIO SILVA DE LIMA
Vice President, Oncology Global Medical Affairs
DION WARREN
Head, U.S. Oncology Business Unit
